People

Claude View

The People

Governance grade: A-. Genpact has institutional-quality governance — an 11-of-12 independent board, a separate independent Chair, 92% say-on-pay support, ~31% combined ownership by FMR/Vanguard/BlackRock, no dual-class shares, no poison pill, and a mandatory 6x-salary share ownership requirement for the CEO. The wart is a $6M off-cycle retention RSU granted to BK Kalra in December 2025 on top of his already-large package, and a 530:1 CEO pay ratio that is structurally high because most of the workforce is in India.

The People Running This Company

Balkrishan "BK" Kalra, President & CEO. Took over from N.V. Tyagarajan in February 2024 after joining Genpact in 1999 — originally as part of the GE Capital International Services team that became Genpact. No MBA, no marquee degree — a 26-year operator who ran the company's largest verticals (BFSI, Consumer Goods, Life Sciences) before the top job. Execution since promotion has been clean: 6.6% revenue growth, 17% growth in Advanced Technology Solutions, 11% adjusted EPS growth in 2025, and the company beat its own guide in each quarter. Beneficial ownership of 992k shares is mostly exercisable options (812k); direct shares are 181k.

Michael Weiner, CFO. Joined 2020 from Avis Budget Group where he was Treasurer and SVP Strategy. 91% of his target comp is at-risk, and his primary spend category is PSUs tied to the same 3-year revenue and adjusted-EPS goals as the CEO.

Piyush Mehta, CHRO and India Country Manager. A Genpact original from the GE days — longest-serving NEO with the largest beneficial stake (456k shares, incl. 368k options exercisable). India P&L ownership matters because ~95% of the 147k+ employee base is outside the U.S.

Anil Nanduru and Riju Vashisht, Business Leaders. Two of the three revenue-line owners. Both long-tenured. One related-party note: Anil Nanduru's sister-in-law Pallavi Nanduru is a VP in HR with compensation above $120k — disclosed, reviewed by audit committee, immaterial.

What to doubt. The board is entirely outsiders-plus-BK — there is no second operator on the board who could credibly push back on the CEO on operating details. The CEO's Dec-2025 $6M retention RSU suggests the board was worried about him leaving during the agentic pivot, which is unusual for a 26-year lifer.

What They Get Paid

Structure is right; absolute level is large. Kalra's $16.3M in 2025 sits above the non-CEO median S&P 400 IT-services peer but below Accenture/Cognizant. 91% of his target comp is at-risk (PSUs with 3-yr revenue + adjusted-EPS goals, plus rTSR modifier vs. S&P 400, and annual RSUs with graded vesting). 78% is long-term equity. PSUs measure the right things — revenue and adjusted EPS — with a relative TSR modifier to keep absolute share-price tailwinds from inflating payouts.

The friction point: Kalra's $6M one-time RSU. Granted Dec 2025, vesting one-third each Dec 2026/2027/2028, explicitly labeled a "retention" grant "to support Mr. Kalra's continued focus on driving the Company's strategic transition to agentic operations." The committee's rationale — that annualized $2M on top of ongoing comp brings Kalra closer to market median — is defensible, but a $6M retention award to a 26-year insider two years into the CEO role is the kind of thing proxy advisors flag.

Are They Aligned?

Ownership concentration is index-fund normal, with one notable long-term shareholder. FMR/Vanguard/BlackRock together hold ~31% — passive index exposure, not activist. The more interesting holder is Nalanda India Equity Fund (Pulak Prasad's Mauritius-domiciled long-only fund) at 7.74% — on file since a 2021 13G and visibly unmoved since. Nalanda is a known quality-compounder buyer; its patient presence at 7%+ is a credible external endorsement.

Insider activity is lopsided to the sell side, but it's the normal lopsided. Every open-market sale in the past 12 months was by someone simultaneously exercising options or cashing vested RSUs — classic post-vest monetization, not a signal. The one exception cuts the other way: director Nick Gangestad bought 2,000 shares on the open market at $43.97 in May 2025 — a small but real signal of confidence from the incoming audit chair.

The largest single sale — 108,880 shares at $54.87 ($5.97M, Feb 2025) — was the departing former CEO N.V. Tyagarajan after stepping off the board in May 2025. Expected, not alarming.

CEO behavior specifically. Kalra has sold 56,400 shares on the open market over 12 months for ~$2.5M. Same period: he received 337,647 shares in grants (including the Dec-2025 $6M retention RSU) and exercised 40,000 options. Net position has grown meaningfully. No programmatic 10b5-1 selling.

Skin-in-the-game: 7/10. Kalra's beneficial ownership of ~992k shares (of which 811k are exercisable options) is ~$36M at the current $36.65 price. That is 2.2x his 2025 total comp and ~40x his base salary — above the 6x requirement. But the bulk is option-heavy, not cash-paid common stock, which makes the alignment slightly cheaper than it reads. 7/10, not 9/10, because (a) most holdings are option-based, not paid-in, (b) the top-5 NEO group is only 1.58% of shares, and (c) the December 2025 retention grant reads as a concession to a CEO with a reasonable — not extraordinary — tolerance for staying.

Capital allocation discipline: strong. In 2025 Genpact returned $401M to shareholders: $283M in buybacks (6M shares at an average $46.16) plus $118M in dividends. Dividend was raised 10% to $0.75/share annualized for 2026. They bought shares at an average price ($46.16) visibly above the current quote ($36.65), which is a minor blemish on timing, but the repurchase pace is sustained and material relative to a $6.2B market cap.

Related-party: trivial. Only disclosed RPT in 2025 is that Anil Nanduru's sister-in-law is a VP in HR earning >$120k. Reviewed and approved by the audit committee. Everything else normal.

Board Quality

The basics are right. 11 of 12 are independent; only Kalra is not. Chair (Madden) and CEO are separate — and Madden has held the chair role as an independent for years, which is the structure serious governance investors want. All three committees are 100% independent. Two audit committee financial experts (Verdi and Gangestad) — Gangestad, a former 3M CFO, is taking over the audit chair in 2026. That's a real upgrade.

Skills coverage — with one gap. The director skills matrix shows 10/10 with senior leadership experience, 10/10 with finance/risk, and 8/10 with innovation/technology. The weakest area is specific AI/agentic-operations expertise on the board itself; the company has delegated AI oversight to the Nominating & Governance Committee starting 2026 and pulls from a management-led Responsible AI Committee. Given that "GenpactNext" is an agentic-AI bet-the-company pivot, the board should arguably add a sitting AI operator in the next refresh cycle. Thimaya Subaiya (ex-Cisco CX, Salesforce) and John Hinshaw (ex-HSBC Group COO, HP EVP) partially fill this — but neither is an AI specialist.

Refreshment is active. Two directors (Agrawal, Franklin) are not standing for re-election in 2026. Four have joined in 2024-2025 (Kalra, Gangestad, Hinshaw, Subaiya). Median tenure 7.8 years. Longest-serving is Madden at 20+. The board is turning over at a steady, not disruptive, pace.

Meeting engagement is adequate. 8 board meetings in 2025 with 92% average attendance; 100% attendance at the 2025 annual meeting by sitting directors. Audit committee met 14 times — unusually active, which is a positive signal given Genpact's cross-border tax exposure and India footprint.

The Verdict

Grade: A-.

Strongest positives.

Independent Chair and 11/12 independent board — the structural basics are all done right.

91% of CEO pay is at-risk, tied to 3-year revenue, adjusted EPS, and relative TSR vs. S&P 400.

92% say-on-pay support in 2025; extensive shareholder engagement led to concrete changes in 2023 (eliminated time-based options, added 3-yr PSU performance period, added rTSR modifier).

Pulak Prasad's Nalanda at 7.7% for 5+ years is the most credible external endorsement you get without an activist.

CEO Kalra is a 26-year lifer, not a parachute hire — institutional knowledge plus clean post-promotion execution.

No poison pill, one share/one vote, anti-hedging/anti-pledging enforced, clawback active.

Real concerns.

The $6M one-time retention RSU to a 26-year lifer two years into the CEO role is defensible on "market median" math but feels like a tell that the board needed to lock Kalra in.

530:1 CEO pay ratio is structural (95% India workforce) but optically hostile.

No sitting AI/agentic operator on the board even though GenpactNext is an agentic pivot.

Directors + officers own only 1.58% of shares — there is no material inside ownership, only compensation-driven alignment.

What would move the grade.

Upgrade to A if Kalra meets the 6x base salary requirement in directly-held (not option) shares and the 2026 proxy shows Nalanda adding or a named AI operator joining the board.

Downgrade to B+ if the 2026 annual RSU awards include another off-cycle special grant, or if say-on-pay drops below 85% (the 2022-2023 compensation-committee changes were the direct response to a prior vote closer to the 85% threshold, so the governance machine has shown it reacts).